热门资讯> 正文

第32季度生物GAAP每股收益为-0.78美元

2025-08-06 19:45

Q32 Bio press release (NASDAQ:QTTB): Q2 GAAP EPS of -$0.78.
Cash and cash equivalents were $54.8 million as of June 30, 2025. Q32 Bio believes its cash and cash equivalents are sufficient to fund operations into 2027, through the SIGNAL-AA OLE and topline results of the SIGNAL-AA Part B trial evaluating bempikibart in patients with AA expected in the first half of 2026.

More on Q32 Bio

Seeking Alpha’s Quant Rating on Q32 Bio
Historical earnings data for Q32 Bio
Financial information for Q32 Bio

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。